Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver North Intersects 1.83 metres True Width of 1,088 g/t Silver, 3.90 g/t Gold (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Healthcare Medical Devices
Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

VentriPoint Diagnostics Ltd > EuropeV4.0 at any time!🚀 Sales Mayo Clinic?Insiders know!😎
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(14)
•••
Comment by jopatcloon Oct 18, 2024 3:31pm
37 Views
Post# 36272289

RE:EuropeV4.0 at any time!🚀 Sales Mayo Clinic?Insiders know!😎

RE:EuropeV4.0 at any time!🚀 Sales Mayo Clinic?Insiders know!😎  I think Jeffrey Soble of Ascend cardiovascular and Beth Rumack, Chief Operating Officer Ollie Hinkle Heart Foundation FDA V4.0 and Sales at any time now Insiders know! more than the negatives that denigrate ventripoint. -“We want to introduce Ventripoint to all our hospital partners, to make it a standard of care,” Beth Rumack, Chief Operating Officer Ollie Hinkle Heart Foundation and now (The Ollie Hinkle Foundation posted videos of their Take Heart 2024 conference on YouTube. In the first session Dr. Soriano of Seattle Children's Hospital provides a very nice overview of VMS+ and its benefits to patients and care providers. Take Heart 2024: Session 1 youtube.com https://www.youtube.com/watch?app=desktop&v=Ucu6uGRMtEs ) -“Our aim is that by working together, we can ultimately provide reliable and effective tools for clinicians on a global scale.” Jeffrey Soble, MD CEO ASCEND (and now and now The BEST Automation and Analytics on PLANET GEN3EHO On Ascend's website https://ascendcv.com/ )
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities